Immunotherapy duo takes on brain tumors in melanoma patients

NCT ID NCT02374242

Ongoing Disease control Sponsor: Melanoma Institute Australia Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the immunotherapy drug nivolumab, alone or combined with ipilimumab, can shrink melanoma tumors that have spread to the brain. About 76 adults with stage IV melanoma and at least one brain metastasis will receive treatment. The main goal is to see how many patients have their brain tumors shrink or disappear.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer melanoma metastatic malignant neoplasm in the brain metastatic melanoma Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN METASTASES MELANOMA

Contacts and locations

Locations

Melanoma Institute Australia

Wollstonecraft, New South Wales, 2065, Australia
Peter MacCallum Cancer Centre

East Melbourne, Victoria, 3002, Australia
Princess Alexandra Hospital

Woolloongabba, Queensland, 4102, Australia
Royal Adelaide Hospital

Adelaide, South Australia, 5000, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.